
Covid catapults Cyrus Poonawalla to richest in pharma
Cyrus Soli Poonawalla’s Serum Institute of India made the most of the country’s demand for vaccines.
Cyrus Soli Poonawalla’s Serum Institute of India made the most of the country’s demand for vaccines.
The owner of world's biggest vaccine maker is also known for his interest in social causes.
While the initial rollout will be for supplies to the government vaccination programme, commercial open sales may begin early 2023, says Adar Poonawalla.
Serum Institute chief executive Adar Poonawalla, during a media event today, said the company has 200 million doses of vaccine stock available currently.
India has learned a lot and is in a stronger and better position to face any future wave or future pandemics, says Adar Poonawalla.
Covid-19 vaccines Corbevax and Covovax, and anti-viral medication Molnupiravir have been granted emergency use authorisation by the CDSCO.
Poonawalla says the biggest learning from the pandemic has been the realisation that one should not make forward looking predictions, as things have been changing fast with Covid-19
WHO chief scientist Soumya Swaminathan congratulated Serum Institute, Adar Poonawalla and Novavax for offering one more highly effective and safe vaccine.
In an exclusive conversation with Fortune India, the executive chairperson of Biocon says India should immediately start mixing and matching existing vaccines to accelerate the vaccination drive.
At a time when the entire world is frantically trying to procure more vaccine doses, it is going to be a protracted struggle for India.